Epidermal growth factor is a critical regulator of the cytokine IL-33 in intestinal epithelial cells

British Journal of Pharmacology

Volumn , Issue , 2016, Pages 2532-2542

  Islam, M S ^a   Horiguchi, K ^b   Iino, S ^b   Kaji, N ^a   Mikawa, S ^a   Hori, M ^a   Ozaki, H ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN SULFATE; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 33; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL LEVEL; COLITIS; COLON CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTESTINE EPITHELIUM CELL; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 84979224117     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13535     Document Type: Article

References (40)

1. Abud HE, Watson N, Heath JK (2005). Growth of intestinal epithelium in organ culture is dependent on EGF signalling. Exp Cell Res 303: 252–262.
2. Alexander SP, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015). The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. Br J Pharmacol 172: 5979–6023.
3. Andoh A, Fujino S, Okuno T, Fujiyama Y, Bamba T (2002). Intestinal subepithelial myofibroblasts in inflammatory bowel diseases. J Gastroenterol 37 (Suppl 14): 33–37.
4. Baekkevold ES, Roussigne M, Yamanaka T, Johansen FE, Jahnsen FL, Amalric F et al. (2003). Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 163: 69–79.
5. Beltran CJ, Nunez LE, Diaz-Jimenez D, Farfan N, Candia E, Heine C et al. (2009). Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis 16: 1097–1107.
6. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461–3471.
7. De Robertis M, Massi E, Poeta ML, Carotti S, Morini S, Cecchetelli L et al. (2011). The AOM/DSS murine model for the study of colon carcinogenesis: from pathways to diagnosis and therapy studies. J Carcinog 10: 9. doi: 10.4103/1477-3163.78279.
8. Frey MR, Golovin A, Polk DB (2004). Epidermal growth factor-stimulated intestinal epithelial cell migration requires Src family kinase-dependent p38 MAPK signaling. J Biol Chem 279: 44513–44521.
9. Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Kuchler AM (2009). Interleukin-33 – cytokine of dual function or novel alarmin? Trends Immunol 30: 227–233.
10. Herbst RS, Fukuoka M, Baselga J (2004). Gefitinib–a novel targeted approach to treating cancer. Nat Rev Cancer 4: 956–965.
11. Hueber AJ, Alves-Filho JC, Asquith DL, Michels C, Millar NL, Reilly JH et al. (2011). IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur J Immunol 41: 2229–2237.
12. Kakkar R, Lee RT (2008). The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 7: 827–840.
13. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577–1579.
14. Kim H, Lee HS, Chang KT, Ko TH, Baek KJ, Kwon NS (1995). Chloromethyl ketones block induction of nitric oxide synthase in murine macrophages by preventing activation of nuclear factor-kappa B. J Immunol 154: 4741–4748.
15. Kobori A, Yagi Y, Imaeda H, Ban H, Bamba S, Tsujikawa T et al. (2010). Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol 45: 999–1007.
16. Lloyd CM (2010). IL-33 family members and asthma – bridging innate and adaptive immune responses. Curr Opin Immunol 22: 800–806.
17. Lopetuso LR, Scaldaferri F, Pizarro TT (2012). Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. Fibrogenesis Tissue Repair 5: 18. doi: 10.1186/1755-1536-5-18.
18. McGrath JC, Lilley E (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189–3193.
19. Miller AM (2011). Role of IL-33 in inflammation and disease. J Inflamm 8: 22. doi: 10.1186/1476-9255-8-22.
20. Mizutani N, Nabe T, Yoshino S (2014). IL-17A promotes the exacerbation of IL-33-induced airway hyperresponsiveness by enhancing neutrophilic inflammation via CXCR2 signaling in mice. J Immunol 192: 1372–1384.
21. Morita H, Arae K, Ohno T, Kajiwara N, Oboki K, Matsuda A et al. (2012). ST2 requires Th2-, but not Th17-, type airway inflammation in epicutaneously antigen-sensitized mice. Allergol Int 61: 265–273.
22. Moussion C, Ortega N, Girard JP (2008). The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’? PLoS One 3: e3331.
23. Nabe T (2014). Interleukin (IL)-33: new therapeutic target for atopic diseases. J Pharmacol Sci 126: 85–91.
24. Nabe T, Wakamori H, Yano C, Nishiguchi A, Yuasa R, Kido H et al. (2015). Production of interleukin (IL)-33 in the lungs during multiple antigen challenge-induced airway inflammation in mice, and its modulation by a glucocorticoid. Eur J Pharmacol 757: 34–41.
25. Nishida A, Andoh A, Imaeda H, Inatomi O, Shiomi H, Fujiyama Y (2009). Expression of interleukin 1-like cytokine interleukin 33 and its receptor complex (ST2L and IL1RAcP) in human pancreatic myofibroblasts. Gut 59: 531–541.
26. Pichery M, Mirey E, Mercier P, Lefrancais E, Dujardin A, Ortega N et al. (2012). Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol 188: 3488–3495.
27. Piechocki MP, Dibbley SK, Lonardo F, Yoo GH (2008). Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu. Int J Cancer 122: 1722–1729.
28. Rao JN, Li L, Bass BL, Wang JY (2000). Expression of the TGF-beta receptor gene and sensitivity to growth inhibition following polyamine depletion. Am J Physiol Cell Physiol 279: C1034–C1044.
29. Real FX, Rettig WJ, Chesa PG, Melamed MR, Old LJ, Mendelsohn J (1986). Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res 46: 4726–4731.
30. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183–232.
31. Scheving LA, Shiurba RA, Nguyen TD, Gray GM (1989). Epidermal growth factor receptor of the intestinal enterocyte. Localization to laterobasal but not brush border membrane. J Biol Chem 264: 1735–1741.
32. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK et al. (2005). IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479–490.
33. Sedhom MA, Pichery M, Murdoch JR, Foligne B, Ortega N, Normand S et al. (2012). Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut 62: 1714–1723.
34. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH et al. (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 44 (Database Issue): D1054–D1068.
35. Tajima S, Bando M, Ohno S, Sugiyama Y, Oshikawa K, Tominaga S et al. (2007). ST2 gene induced by type 2 helper T cell (Th2) and proinflammatory cytokine stimuli may modulate lung injury and fibrosis. Exp Lung Res 33: 81–97.
36. Talabot-Ayer D, McKee T, Gindre P, Bas S, Baeten DL, Gabay C et al. (2011). Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine 79: 32–37.
37. Taniguchi K, Yamamoto S, Hitomi E, Inada Y, Suyama Y, Sugioka T et al. (2014). Interleukin 33 is induced by tumor necrosis factor alpha and interferon gamma in keratinocytes and contributes to allergic contact dermatitis. J Investig Allergol Clin Immunol 23: 428–434.
38. Tzouvelekis A, Ntolios P, Karameris A, Vilaras G, Boglou P, Koulelidis A et al. (2013). Increased expression of epidermal growth factor receptor (EGF-R) in patients with different forms of lung fibrosis. Biomed Res Int 2013: 654354.
39. Willems S, Hoefer I, Pasterkamp G (2012). The role of the Interleukin 1 receptor-like 1 (ST2) and Interleukin-33 pathway in cardiovascular disease and cardiovascular risk assessment. Minerva Med 103: 513–524.
40. Yagami A, Orihara K, Morita H, Futamura K, Hashimoto N, Matsumoto K et al. (2010). IL-33 mediates inflammatory responses in human lung tissue cells. J Immunol 185: 5743–5750.